Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Sermonix Pharmaceuticals

Sermonix Pharmaceuticals is an Ohio LLC privately held biotechnology company with a targeted focus towards bringing female-specific oncology products through proof of concept, preclinical, and clinical development with a clear regulatory pathway in place.

## Sitemaps

- [XML Sitemap](https://sermonixpharma.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”](https://sermonixpharma.com/athira-pharma-announces-name-change-to-leonabio-inc-with-new-ticker-lona/)
- [Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million](https://sermonixpharma.com/athira-pharma-announces-exclusive-license-to-lasofoxifene-phase-3-development-program-for-metastatic-breast-cancer-candidate-and-a-financing-for-up-to-236-million/)
- [Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting](https://sermonixpharma.com/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67-suppression-in-phase-2-i-spy-2-arm-evaluating-therapy-in-neoadjuvant-breast-cancer-setting/)
- [Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics](https://sermonixpharma.com/sermonix-and-regor-announce-strategic-collaboration-to-optimize-regors-proprietary-rcard-platform-for-identification-of-novel-targets-and-therapeutics/)
- [Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer](https://sermonixpharma.com/sermonix-announces-clinical-breast-cancer-publication-of-article-examining-effects-of-lasofoxifene-versus-fulvestrant-on-urogenital-symptoms-in-patients-with-esr1-mutated-er-her2-metastatic-breast-c/)
- [Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference](https://sermonixpharma.com/sermonix-pharmaceuticals-to-host-oral-presentation-on-vaginal-and-sexual-health-at-rise-up-for-breast-cancer-conference/)
- [Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting](https://sermonixpharma.com/sermonix-pharmaceuticals-completes-enrollment-of-phase-2-i-spy-2-arm-evaluating-lasofoxifene-in-neoadjuvant-breast-cancer-setting/)
- [Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations](https://sermonixpharma.com/sermonix-pharmaceuticals-receives-u-s-patent-for-lasofoxifene-as-method-for-treating-aromatase-resistant-er-breast-cancer-in-the-absence-of-esr1-mutations/)
- [Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-breast-cancer-research-publication-of-paper-examining-lasofoxifenes-preclinical-effects-on-aromatase-inhibitor-resistant-non-esr1-mutated-breast-cancer/)
- [Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-chinese-approval-of-investigational-new-drug-application-for-lasofoxifene/)
- [Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-menopause-journal-publication-of-article-on-oral-lasofoxifenes-effects-on-vaginal-atrophy-in-postmenopausal-women/)
- [Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape](https://sermonixpharma.com/sermonix-to-host-kol-fireside-chat-on-advancements-in-the-metastatic-breast-cancer-treatment-landscape/)
- [Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-mbc-alliance-membership-new-discover-elaine-website/)
- [Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene](https://sermonixpharma.com/henlius-and-sermonix-announce-strategic-collaboration-and-exclusive-license-agreements-for-novel-endocrine-therapy-lasofoxifene/)
- [Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life](https://sermonixpharma.com/sermonix-pharmaceuticals-shares-resuits-of-third-survey-on-esr1-and-metastatic-breast-cancer-patient-quality-of-life/)
- [Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations](https://sermonixpharma.com/sermonix-pharmaceuticals-shares-pharmacokinetic-and-baseline-genomic-clinical-data-tied-to-elaine-lasofoxifene-trials-of-patients-with-esr1-mutations/)
- [Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-publication-of-elaine-1-and-elaine-2-trial-results-in-annals-of-oncology/)
- [Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-five-abstracts-accepted-for-presentation-at-2023-san-antonio-breast-cancer-symposium/)
- [Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-jco-precision-oncology-publication-of-case-report-on-a-complete-remission-in-a-metastatic-breast-cancer-patient-participating-in-elaine-1-trial/)
- [Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-results-of-elaine-1-exploratory-analysis-evaluating-effect-of-patient-characteristics-on-baseline-genitourinary-symptoms/)
- [Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer](https://sermonixpharma.com/sermonix-pharmaceuticals-shares-results-of-equals-2-survey-on-vaginal-and-sexual-health-in-patients-with-er-her2-metastatic-breast-cancer/)
- [Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference](https://sermonixpharma.com/sermonix-pharmaceuticals-shares-encore-elaine-2-poster-presentation-at-2023-metastatic-breast-cancer-research-conference/)
- [Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting](https://sermonixpharma.com/sermonix-pharmaceuticals-to-present-two-posters-at-the-menopause-society-2023-annual-meeting/)
- [Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-article-comparing-traditional-to-just-in-time-trial-enrollment-models-is-published-in-jco-clinical-cancer-informatics/)
- [Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women’s Sexual Health Annual Meeting 2023](https://sermonixpharma.com/sermonix-to-present-poster-comparing-lasofoxifene-and-fulvestrant-effect-on-vaginal-health-at-international-society-for-the-study-of-womens-sexual-health-annual-meeting-2023/)
- [Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer](https://sermonixpharma.com/sermonix-pharmaceuticals-shares-ascposter-presentation-on-longer-patient-follow-up-results-for-elain-2-study-in-esr1-mutated-metastatic-breast-cancer/)
- [Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023](https://sermonixpharma.com/sermonix-pharmaceuticals-to-share-longer-patient-follow-up-results-for-elaine-2-in-poster-presentation-at-asco-2023/)
- [Sermonix Pharmaceuticals Announces E-Poster Presentation on I-SPY 2 Study of Neoadjuvant Lasofoxifene at St. Gallen International Breast Cancer Conference 2023](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-e-poster-presentation-on-i-spy-2-study-of-neoadjuvant-lasofoxifene-at-st-gallen-international-breast-cancer-conference-2023/)
- [Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-initiation-of-phase-3-elaine-3-study-of-lasofoxifene-plus-abemaciclib-in-pre-and-post-menopausal-patients-with-locally-advanced-or-metastatic-er-her2-breast-cance/)
- [Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation](https://sermonixpharma.com/sermonixs-lasofoxifene-improves-vaginal-vulvar-symptoms-relative-to-fulvestrant-in-elain1-study-of-postmenopausal-women-with-locally-advanced-or-metastatic-er-her2-breast-cancer-and-an-esr1-mutation/)
- [Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial](https://sermonixpharma.com/sermonix-pharmaceuticals-and-quantum-leap-healthcare-announce-new-study-arm-to-evaluate-lasofoxifene-in-ongoing-i-spy-2-clinical-trial/)
- [Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene](https://sermonixpharma.com/sermonix-shares-two-recently-presented-posters-evaluating-esr1-mutations-in-circulating-tumor-dna-from-patients-with-er-her2-metastatic-breast-cancer-who-were-treated-with-lasofoxifene/)
- [Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns](https://sermonixpharma.com/sermonix-shares-two-posters-at-sabcs-2022-on-er-her2-metastatic-breast-cancer-patient-survey-about-knowledge-of-ngs-and-esr1-mutations-quality-of-life-concerns/)
- [Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-poster-presentation-on-phase-1-ethnobridging-study-of-lasofoxifene-at-the-12th-aacr-jca-joint-conference-breakthroughs-in-cancer-research-translating-know/)
- [Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-four-abstracts-accepted-for-presentation-at-2022-san-antonio-breast-cancer-symposium/)
- [Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen](https://sermonixpharma.com/sermonix-pharmaceuticals-shares-details-of-first-ever-known-durable-complete-clinical-response-in-a-metastatic-er-her2-breast-cancer-patient-with-an-esr1-mutation-after-prior-cdk4-6-inhibitor-treatm/)
- [Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-results-of-phase-2-study-of-lasofoxifene-vs-fulvestrant-in-postmenopausal-women-with-locally-advanced-or-metastatic-er-her2-breast-cancer-and-an-esr1-mutation/)
- [Sermonix Pharmaceuticals Announces Top-Line Data From ELAINE 1 Phase 2 Study of Lasofoxifene Versus Fulvestrant Is Accepted for a Late-Breaking Oral Presentation at ESMO Congress 2022](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-top-line-data-from-elaine-1-phase-2-study-of-lasofoxifene-versus-fulvestrant-is-accepted-for-a-late-breaking-oral-presentation-at-esmo-congress-2022/)
- [Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs](https://sermonixpharma.com/sermonix-to-host-virtual-clinical-update-on-its-elaine-phase-2-clinical-programs/)
- [Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions](https://sermonixpharma.com/sermonix-pharmaceuticals-phase-2-lasofoxifene-trial-poster-receives-a-grasp-advocate-choice-award-selected-for-post-asco-patient-advocate-investigator-discussions/)
- [Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting](https://sermonixpharma.com/sermonix-to-present-updated-data-from-elaine-2-clinical-trial-of-lasofoxifene-in-combination-with-abemaciclib-in-women-with-locally-advanced-or-metastatic-erher2-breast-cancer-and-an-esr1-mutation-aft/)
- [Sermonix Announces Abstracts Accepted for Presentation at the  2022 American Society of Clinical Oncology (ASCO) Annual Meeting](https://sermonixpharma.com/sermonix-announces-abstracts-accepted-for-presentation-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/)
- [Biotech raises $40M to test forgotten osteoporosis drug in treatment-resistant breast cancer](https://sermonixpharma.com/biotech-raises-40m-to-test-forgotten-osteoporosis-drug-in-treatment-resistant-breast-cancer/)
- [Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-poster-presentation-at-the-2021-san-antonio-breast-cancer-symposium/)
- [Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020](https://sermonixpharma.com/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020/)
- [Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II](https://sermonixpharma.com/sermonix-pharmaceuticals-closes-40-million-series-a3-financing-round-led-by-perceptive-xontogeny-ventures-fund-ii/)
- [Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying ...](https://sermonixpharma.com/sermonix-pharmaceuticals-completes-enrollment-of-phase-2-clinical-trial-collaboration-studying/)
- [Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-breast-cancer-research-publication-of-preclinical-lasofoxifene-study-in-endocrine-resistant-breast-cancer/)
- [Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer](https://sermonixpharma.com/sermonix-pharmaceuticals-project-with-huntsman-cancer-institute-researcher-to-investigate-potential-effects-of-lasofoxifene-on-esr1-mutations-in-endometrial-cancer/)
- [Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors](https://sermonixpharma.com/sermonix-pharmaceuticals-names-dr-elizabeth-garner-to-its-board-of-directors/)
- [Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020](https://sermonixpharma.com/sermonix-to-present-poster-on-patient-awareness-of-esr1-mutation-biomarker-testing-attitudes-on-metastatic-breast-cancer-quality-of-life-at-virtual-san-antonio-breast-cancer-symposium-2020/)
- [Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib](https://sermonixpharma.com/sermonix-doses-first-patient-in-phase-2-clinical-trial-collaboration-studying-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib/)
- [Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada](https://sermonixpharma.com/sermonix-pharmaceuticals-partners-with-exactis-innovation-for-elaine-1-clinical-trial-sites-in-canada/)
- [Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting](https://sermonixpharma.com/sermonix-to-present-poster-on-lasofoxifene-cdk-4-6-inhibitor-combination-for-aacr-virtual-annual-meeting/)
- [Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer](https://sermonixpharma.com/sermonix-pharmaceuticals-to-collaborate-with-eli-lilly-and-company-in-studying-combination-of-lasofoxifene-and-lillys-cdk-4-and-6-inhibitor-abemaciclib-in-metastatic-breast-cancer/)
- [Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer](https://sermonixpharma.com/sermonix-to-present-poster-at-endo-2019-on-lasofoxifenes-potent-anti-tumor-activity-in-esr1-hormone-resistant-breast-cancer/)
- [Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment](https://sermonixpharma.com/sermonix-to-present-at-boston-oncology-investor-conference-on-potential-for-lasofoxifene-in-metastatic-breast-cancer-treatment/)
- [Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors](https://sermonixpharma.com/sermonix-pharmaceuticals-adds-three-new-members-to-its-board-of-directors/)
- [Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting](https://sermonixpharma.com/sermonix-to-present-poster-on-lasofoxifene-as-a-potential-treatment-for-er-metastatic-breast-cancer-at-2019-asco-annual-meeting/)
- [Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene](https://sermonixpharma.com/sermonix-receives-fda-fast-track-designation-for-investigational-drug-lasofoxifene/)
- [Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer](https://sermonixpharma.com/lasofoxifene-shows-promise-as-treatment-for-er-positive-metastatic-breast-cancer/)
- [Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations](https://sermonixpharma.com/sermonix-poster-presentation-at-2019-asco-annual-meeting-demonstrates-promise-for-lasofoxifene-in-treating-er-metastatic-breast-cancer-patients-with-esr1-mutations/)
- [Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting](https://sermonixpharma.com/sept-26-presentation-in-chicago-demonstrates-the-need-for-improvement-in-practitioners-understanding-of-patients-intimacy-concerns/)
- [Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer](https://sermonixpharma.com/sermonix-doses-first-patient-in-phase-2-clinical-trial-of-lasofoxifene-for-targeted-precision-medicine-treatment-of-women-with-esr1-mutations-in-metastatic-breast-cancer/)
- [Sermonix to Co-sponsor ‘Candid Conversations’ Patient Advocacy Panel With Breastcancer.org at San Antonio Breast Cancer Symposium](https://sermonixpharma.com/discussion-will-examine-sexual-health-and-intimacy-bone-health-joint-and-muscle-pain-and-quality-of-life-issues-in-metastatic-breast-cancer/)

## Pages

- [Homepage](https://sermonixpharma.com/)
- [Partners & Collaborations](https://sermonixpharma.com/partners-collaborations/)
- [About Expanded Access](https://sermonixpharma.com/about-expanded-access/)
- [The Elaine 3 Study](https://sermonixpharma.com/the-elaine-3-study/)
- [The Elaine Study](https://sermonixpharma.com/the-elaine-study/)
- [The Elaine 2 Study](https://sermonixpharma.com/the-elaine-2-study/)
- [News](https://sermonixpharma.com/news/)
- [Posters & Presentations](https://sermonixpharma.com/medical-meetings/)
- [Media](https://sermonixpharma.com/media/)
- [Who is Elaine?](https://sermonixpharma.com/who-is-elaine/)
- [Contact](https://sermonixpharma.com/contact/)
- [EQUALS](https://sermonixpharma.com/equals/)
- [Breast Cancer](https://sermonixpharma.com/breast-cancer/)
- [Lasofoxifene](https://sermonixpharma.com/lasofoxifene/)
- [Company Overview](https://sermonixpharma.com/about/)
- [Board of Directors](https://sermonixpharma.com/board-of-directors/)
- [Management Team](https://sermonixpharma.com/bios/)
- [Oncology Steering Committee](https://sermonixpharma.com/oncology-steering-committee/)

## Categories

- [News](https://sermonixpharma.com/category/news/)